Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.69 |
| ▸ | DRD1 | P21728 | 1/20 | 0.68 |
| ▸ | DRD4 | P21917 | 1/20 | 0.68 |
| ▸ | DRD5 | P21918 | 1/20 | 0.68 |
| ▸ | DRD3 | P35462 | 1/20 | 0.68 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.68 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.68 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.67 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3331807 | 0.92 | DRD2 (0.84) | DRD2SLC18A3DRD1DRD4DRD5 | |
| SCHEMBL1546830 | 0.91 | DRD2 (0.83) | DRD2SLC18A3DRD1DRD4DRD5 | |
| SCHEMBL1546828 | 0.91 | DRD2 (0.83) | DRD2SLC18A3DRD1DRD4DRD5 | |
| SCHEMBL3397550 | 0.90 | DRD2 (0.81) | DRD2SLC18A3DRD1DRD4DRD5 | |
| SCHEMBL152587 | 0.89 | DRD2 (0.81) | DRD2SLC18A3DRD1DRD4DRD5 | |
| SCHEMBL256656 | 0.88 | DRD2 (0.78) | DRD2SLC18A3DRD1DRD4DRD5 | |
| SCHEMBL27571644 | 0.86 | DRD2 (0.76) | DRD2SLC18A3DRD1DRD4DRD5 | |
| SCHEMBL15779804 | 0.86 | DRD2 (0.76) | DRD2SLC18A3DRD1DRD4DRD5 | |
| SCHEMBL1003503 | 0.85 | DRD2 (0.73) | DRD2SLC18A3DRD1DRD4DRD5 | |
| SCHEMBL8351025 | 0.84 | DRD2 (0.75) | DRD2SLC6A4SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020214336-A9 | SULFUR-HETEROCYCLE EXCHANGE CHEMISTRY AND USES THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-11-19 | — | — | WO | disclosed |
| WO-2020214336-A2 | SULFUR-HETEROCYCLE EXCHANGE CHEMISTRY AND USES THEREOF | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2020-10-22 | — | — | WO | disclosed |
| EP-2900241-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2018-08-08 | — | — | EP | disclosed |
| WO-2018136555-A2 | PHOTOREACTIVE LIGANDS AND USES THEREOF | THE SCRIPPS RESEARCH INSTITUTE (US) | 2018-07-26 | — | — | WO | disclosed |
| EP-2900223-B1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME (US) | 2017-10-25 | — | — | EP | disclosed |
| US-RE46117-E1 | Modulators of dopamine neurotransmission | TEVA PHARMACEUTICALS INTERNATIONAL GMBH (CH) | 2016-08-23 | — | — | US | disclosed |
| US-9233979-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-12 | — | — | US | disclosed |
| US-9226922-B2 | Compounds that are ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | US | disclosed |
| EP-0844097-B1 | Thermal paper with security features and security ink therefor | NCR INT INC (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2001046145-A1 | NEW MODULATORS OF DOPAMINE NEUROTRANSMISSION | A. CARLSSON RESEARCH AB (SE) | 2001-06-28 | — | — | WO | disclosed |
| US-6106910-A | PRINT MEDIUM HAVING A SENSE MARK COMPRISED OF A NEAR INFRARED FLUORESCENT (NIRF) COMPONENT THAT TRIGGERS AUTOMATED OPERATIONS WITHOUT INTERFERENCE FROM PRINTED TEXT OR IMAGES ON THE SUBSTRATE; NIRF PIGMENTS PROTECTED FROM AIR WITH RESIN | NCR CORPORATION (US) | 2000-08-22 | — | — | US | disclosed |
| US-6060426-A | THERMOSENSITIVE COATING WITH NEAR INFRARED FLUORESCENT COMPOUND | NCR CORPORATION (US) | 2000-05-09 | — | — | US | disclosed |
| EP-0933227-A2 | Print media with near infrared fluorescent sense mark and printer therefor | NCR INTERNATIONAL INC. (US) | 1999-08-04 | — | — | EP | disclosed |
| EP-0933228-A1 | Thermosensitive recording material | NCR INTERNATIONAL INC. (US) | 1999-08-04 | — | — | EP | disclosed |
| US-5883043-A | Thermal paper with security features | NCR CORPORATION (US) | 1999-03-16 | — | — | US | disclosed |
| EP-0844097-A1 | Thermal paper with security features and security ink therefor | NCR INTERNATIONAL INC. (US) | 1998-05-27 | — | — | EP | disclosed |
| US-5741592-A | Microsencapsulated system for thermal paper | NCR CORPORATION (US) | 1998-04-21 | — | — | US | disclosed |
| EP-0325755-B1 | Tricyclic compounds | KYOWA HAKKO KOGYO KK (JP) | 1994-03-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266895-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK10, MAP3K1 | DRD2 4744/4885SLC18A3 4082/4885DRD1 4557/4885 |
| US-20150258074-A1 | NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | MAPK1, MAPK4, MAP3K20 | DRD2 4161/4885SLC18A3 3374/4885DRD1 3659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.